Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
|||
| Line 9: | Line 9: | ||
== Patient Drug Information== | == Patient Drug Information== | ||
| − | *[https://products.sanofi.us/Cablivi/Cablivi.pdf Caplacizumab (Cablivi) Package Insert]<ref>[https://products.sanofi.us/Cablivi/Cablivi.pdf Caplacizumab (Cablivi) Package Insert]</ref><ref>[[ | + | *[https://products.sanofi.us/Cablivi/Cablivi.pdf Caplacizumab (Cablivi) Package Insert]<ref>[https://products.sanofi.us/Cablivi/Cablivi.pdf Caplacizumab (Cablivi) Package Insert]</ref><ref>[[File:Cablivi.pdf | Caplacizumab (Cablivi) package insert (locally hosted backup)]]</ref> |
==Also known as== | ==Also known as== | ||
Revision as of 22:57, 19 September 2021
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi